Carpenter Technology to Participate at the Cowen Aerospace/Defense & Industrials Conference
Get Alerts CRS Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.2%
EPS Growth %: +25.1%
Join SI Premium – FREE
PHILADELPHIA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) announced today that Tony Thene, President and Chief Executive Officer, will participate at the Cowen Aerospace/Defense & Industrials Conference on Wednesday, February 9, 2022. Mr. Thene’s webcast presentation will be available on the investor relations section of Carpenter’s website at https://ir.carpentertechnology.com. A replay of the webcast will also be available following the live presentation.
Cowen Aerospace/Defense & Industrials Conference
Date: Wednesday, February 9, 2022
Time: 1:30 PM ET
About Carpenter Technology
Carpenter Technology Corporation is a recognized leader in high-performance specialty alloy-based materials and process solutions for critical applications in the aerospace, defense, transportation, energy, industrial, medical, and consumer electronics markets. Founded in 1889, Carpenter Technology has evolved to become a pioneer in premium specialty alloys, including titanium, nickel, and cobalt, as well as alloys specifically engineered for additive manufacturing (AM) processes and soft magnetics applications. Carpenter Technology has expanded its AM capabilities to provide a complete “end-to-end” solution to accelerate materials innovation and streamline parts production. More information about Carpenter Technology can be found at www.carpentertechnology.com.
| Media Inquiries: | Investor Inquiries: |
| Heather Beardsley | The Plunkett Group |
| +1 610-208-2278 | Brad Edwards |
| [email protected] | +1 914-582-4187 |
| [email protected] |
Source: Carpenter Technology Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RCI BANQUE : PLACEMENT OF A 890.2 MILLION EURO SECURITISATION BACKED BY SPANISH AUTO LOANS
- Funding Perpetuals Becomes MyFundedPerps, Joining the MyFundedFutures Family
- Applied Biologics Achieves Key Preclinical Milestone in Disease-Modifying Osteoarthritis Gene Therapy Program
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share